Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Healthy Subjects

Interventions

DRUG

(Treatment A)

Four 100-mg capsules of pacritinib administered as a single oral dose

DRUG

(Treatment B)

A single 80-mg oral solution dose of pacritinib

Trial Locations (1)

Covance Clinical Research Unit, Daytona Beach